Your browser doesn't support javascript.
loading
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.
Bisogno, Gianni; Jenney, Meriel; Bergeron, Christophe; Gallego Melcón, Soledad; Ferrari, Andrea; Oberlin, Odile; Carli, Modesto; Stevens, Michael; Kelsey, Anna; De Paoli, Angela; Gaze, Mark N; Martelli, Helene; Devalck, Christine; Merks, Johannes H; Ben-Arush, Myriam; Glosli, Heidi; Chisholm, Julia; Orbach, Daniel; Minard-Colin, Veronique; De Salvo, Gian Luca.
Afiliação
  • Bisogno G; Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy. Electronic address: gianni.bisogno@unipd.it.
  • Jenney M; Department of Paediatric Oncology, Children's Hospital for Wales, Cardiff, UK.
  • Bergeron C; Institut d'Hématologie et d'Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France.
  • Gallego Melcón S; Servicio de Oncología y Hematología Pediatrica, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Ferrari A; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Oberlin O; Department of Pediatric and Adolescent Oncology, Gustave-Roussy, Villejuif, France.
  • Carli M; Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy.
  • Stevens M; Department of Paediatric Oncology, Bristol Royal Hospital for Children, Bristol, UK.
  • Kelsey A; Department of Paediatric Histopathology, Royal Manchester Children's Hospital, Manchester, UK.
  • De Paoli A; Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
  • Gaze MN; Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Martelli H; Department of Paediatric Surgery, Hôpital Bicêtre-Hôpitaux Universitaires Paris Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, Paris, France.
  • Devalck C; Pediatric Hematology and Oncology, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium.
  • Merks JH; Department of Pediatric Oncology Emma Children's Hospital-Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
  • Ben-Arush M; The Joan and Sanford Weill Pediatric Hematology Oncology and Bone Marrow Transplantation Division, The Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel.
  • Glosli H; Department of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
  • Chisholm J; Children and Young Peoples Unit, The Royal Marsden Hospital, Surrey, UK.
  • Orbach D; SIREDO Oncology Center, Institut Curie, PSL University, Paris, France.
  • Minard-Colin V; Department of Pediatric and Adolescent Oncology, Gustave-Roussy, Villejuif, France.
  • De Salvo GL; Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
Lancet Oncol ; 19(8): 1061-1071, 2018 08.
Article em En | MEDLINE | ID: mdl-29941280

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de publicação: Reino Unido